Rhumbline Advisers Cuts Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Rhumbline Advisers has reduced its stake in Agios Pharmaceuticals by 8.1%, selling 7,666 shares to hold a total of 86,842 shares worth approximately $2.54 million.
• CEO Brian Goff sold 18,700 shares at an average price of $33.54, resulting in a 15.07% decrease in his ownership of the company.
• Agios Pharmaceuticals reported a $1.93 earnings per share for the last quarter, missing estimates, while revenue of $12.50 million surpassed analyst predictions of $9.46 million.

Rhumbline Advisers trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,842 shares of the biopharmaceutical company's stock after selling 7,666 shares during the period. Rhumbline Advisers owned approximately 0.15% of Agios Pharmaceuticals worth $2,544,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $39,000. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the first quarter worth about $40,000. CWM LLC grew its stake in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 996 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 499 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth about $133,000.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,770 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the sale, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the business's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the sale, the insider owned 868 shares in the company, valued at $32,003.16. This represents a 90.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,994 shares of company stock worth $2,341,232 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

AGIO has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Scotiabank reduced their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Finally, Bank of America reduced their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded down $0.30 during mid-day trading on Wednesday, reaching $36.42. 621,660 shares of the company's stock were exchanged, compared to its average volume of 753,277. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The firm has a 50-day moving average price of $37.69 and a two-hundred day moving average price of $33.30. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 3.31 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.